MOLNOVA
HIT YOUR RESEARCH TO LEAD

# Datasheet (Version 1.0)

| | | |
|---|---|---|
| **Product Name** | : | Rogaratinib |
| **Synonyms** | : | BAY1163877 |
| **Cat No.** | : | M22071 |
| **CAS Number** | : | 1443530-05-9 |
| **Molecular Formula** | : | C23H26N6O3S |
| **Formula Weight** | : | 466.56 |
| **Chemical Name** | : | —— |
| **Description** | : | Rogaratinib is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity. A novel pan-FGFR inhibitor, rogaratinib, in biochemical, cellular and in vivo efficacy studies in a variety of preclinical cancer models.?In vitro kinase activity assays demonstrate that rogaratinib potently and selectively inhibits the activity of FGFRs 1, 2, 3 and 4.?In line with this, rogaratinib reduced proliferation in FGFR-addicted cancer cell lines of various cancer types including lung, breast, colon and bladder cancer.?FGFR and ERK phosphorylation interruption by rogaratinib treatment in several FGFR-amplified cell lines suggests that the anti-proliferative effects are mediated by FGFR/ERK pathway inhibition. |
| **Pathway** | : | Angiogenesis |
| **Target** | : | FGFR |
| **Receptor** | : | FGFR |
| **Solubility** | : | DMSO : 5.5 mg/mL (11.78 mM; Need ultrasonic) |
| **SMILES** | : | COCC1=C(CN2CCNC(=O)C2)N2N=CN=C(N)C2=C1C1=CC2=C(S1)C(OC)=CC(C)=C2 |
| **Storage** | : | (-20℃) |
| **Stability** | : | ≥ 2 years |
| **Reference** | : | |




1. Sylvia Grünewald , Oliver Politz , Sebastian Bender,et al.Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.Int J Cancer. 2019 Sep 1;145(5):1346-1357. 2. Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 2016 Jul 18;5(7):e241.